EP Wealth Advisors LLC Has $5.86 Million Stake in Danaher Co. (NYSE:DHR)

EP Wealth Advisors LLC lifted its stake in shares of Danaher Co. (NYSE:DHR) by 3.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,472 shares of the conglomerate’s stock after acquiring an additional 850 shares during the period. EP Wealth Advisors LLC’s holdings in Danaher were worth $5,864,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Gilbert & Cook Inc. raised its holdings in Danaher by 4.9% during the fourth quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after buying an additional 86 shares during the last quarter. Jones Financial Companies Lllp raised its stake in shares of Danaher by 144.0% in the fourth quarter. Jones Financial Companies Lllp now owns 2,086 shares of the conglomerate’s stock worth $483,000 after purchasing an additional 1,231 shares during the last quarter. CWA Asset Management Group LLC boosted its position in shares of Danaher by 14.2% during the fourth quarter. CWA Asset Management Group LLC now owns 3,235 shares of the conglomerate’s stock valued at $748,000 after buying an additional 402 shares during the last quarter. NEOS Investment Management LLC grew its holdings in Danaher by 39.2% during the fourth quarter. NEOS Investment Management LLC now owns 9,337 shares of the conglomerate’s stock worth $2,160,000 after buying an additional 2,631 shares in the last quarter. Finally, Belpointe Asset Management LLC lifted its stake in Danaher by 26.1% during the 4th quarter. Belpointe Asset Management LLC now owns 5,046 shares of the conglomerate’s stock valued at $1,168,000 after acquiring an additional 1,044 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Robert W. Baird raised their price target on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Wells Fargo & Company started coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Barclays upped their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Evercore ISI cut their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by insiders.

Danaher Trading Up 0.9 %

Shares of DHR opened at $278.02 on Tuesday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The stock has a market cap of $205.93 billion, a PE ratio of 47.12, a P/E/G ratio of 4.55 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average price is $270.77 and its 200-day moving average price is $258.06.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the firm posted $2.05 EPS. Danaher’s revenue was down 2.9% on a year-over-year basis. On average, equities analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. Danaher’s payout ratio is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.